Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

On March 10, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 taking place virtually from April 10 – 15, 2021 (Press release, Zymeworks, MAR 10, 2021, View Source [SID1234576407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentations will be available on Saturday, April 10 at 8:30 am ET on the conference website as well as the Zymeworks website.

Presentation Details

Title: PROTECT, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Abstract: 924
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies

Title: Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Abstract: 1788
Session Category: Immunology
Session Title: Modifiers of the Tumor Microenvironment

Title: Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Abstract: 1737
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions

Title: Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abstract: 1032
Session Category: Experimental and Molecular Therapeutics
Session Title: Cellular Responses to Anticancer Drugs

Title: The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Abstract: 1005
Session Category: Experimental and Molecular Therapeutics
Session Title: Cellular Responses to Anticancer Drugs